Ennov Alternatives for Regulatory, Quality and Promotional Material Review Teams

Why teams start looking for an Ennov alternative

Rarely because the platform failed. Usually because one function inside a company has outgrown the shared compromise. A suite serves regulatory, quality, clinical, safety and commercial teams from one architecture, which is precisely why it is affordable, and precisely why each of those teams eventually finds a place where the shared model does not match how their work is actually done. Regulatory wants a registration matrix that behaves the way their product portfolio behaves. Quality wants deviation handling shaped to their process. Commercial wants promotional review that understands digital assets rather than documents.

The second reason is people. Mid market platforms have smaller consultant and contractor ecosystems than the market leader, so when your one internal expert leaves, replacing that knowledge takes longer. That is not a criticism of the software. It is a structural feature of buying outside the dominant platform, and it should be priced into the decision rather than discovered during a resignation.

The third is volume growth in promotional review specifically. A commercial team that produced forty pieces a year now produces several hundred digital assets, most of which are variants of the same underlying claims, and a review system built around documents starts to feel like a queue rather than a control.

What Ennov genuinely does well

The unified architecture is the product. Running regulatory information, quality processes, clinical documents, safety and promotional review on one platform means one validation baseline, one security model, one set of user training and one commercial relationship. Companies that instead assemble four best of breed systems discover the integration and validation cost of that choice within a year, and it is not small.

The commercial positioning is also honest. Mid sized pharma and device companies frequently cannot justify the market leading platform's total cost of ownership, and the alternative is not nothing, it is shared drives and email approvals. A capable suite at a mid market price is a genuinely good outcome for a company at that stage, and European companies in particular have found it a natural fit.

For promotional review, having the approved document, the references it cites and the approval record in one governed place matters more than it sounds. Promotional material carries documented obligations, including submission of pieces at first use in the United States, so the record of what was approved, by whom and against which references has to survive inspection. A suite that keeps content and approvals together does that job.

Where the unified suite bends

Generic review workflow is the first bend. Medical, legal and regulatory review has a rhythm: parallel reviewer input, annotation against a specific claim, referenced evidence attached at the point of the claim, then a version that resolves comments without losing the audit trail. Systems built on document management handle the routing and the record faithfully, and the reviewing experience is where teams feel friction, especially reviewers who do this occasionally rather than daily.

Digital assets are the second. When the unit of review is a website section, an email variant, a social post family or an interactive detail aid, treating each as a document creates a combinatorial explosion. Fifty variants of one message become fifty review cycles, and reviewers see the same claim repeatedly with no memory that they already approved it last month.

Reporting is the third. Cycle time by reviewer, first pass approval rate, the reasons pieces get rejected, which claims generate the most rework: these are the metrics that tell a commercial team where the bottleneck is, and record oriented systems tend to report on records rather than on flow.

The fourth is configuration ceiling by function. Every module in a suite is designed against the average customer of that discipline. The further your process sits from that average, the more you rely on convention and training rather than on the system enforcing your rules.

Your realistic options

• Stay and simplify the process. Most promotional review pain is process, not software: too many reviewers, no triage by risk, no distinction between a new claim and a formatting change. Introduce tiered review before you price anything, because a new platform will faithfully reproduce your current queue.
• Switch to a specialist per function. Purpose built promotional review, purpose built regulatory information management, purpose built quality. Better fit per discipline, more integration and validation work, more vendors to manage.
• Move up to the market leading platform. Defensible if you have grown into it and your partners already work there. Expect a step change in total cost of ownership and a longer implementation.
• Keep the suite, build the claims layer. Hold approved claims and their references as structured, reusable objects, assemble assets from them, and route only genuinely new content through full review. This is the single most effective change available to a commercial team.
• Build a full custom review platform. Worth it when review throughput directly constrains commercial activity, and when digital channel volume is high and growing.

When a custom build pays back

Do the arithmetic on rework, not on licences. Count the pieces submitted for review in a year, the proportion that come back for revision, and the number of reviewer hours consumed. In most commercial teams the majority of that effort is spent re examining claims that were already approved, in a new layout or a new channel. A claims library that carries approved language with its references attached, plus asset assembly from approved components, structurally reduces the number of full reviews rather than making each one marginally faster. That is the difference between a tool and a change.

The second case is launch pressure. Companies preparing a launch generate an enormous burst of material against a fixed date, and review capacity becomes the constraint on commercial readiness. Owning the workflow means you can add triage rules, parallel routing and channel specific paths in weeks rather than requesting them.

The third is a portfolio with genuinely distinct review needs, for example a company with both prescription products and devices, where the rules, reviewers and record obligations differ and one workflow serves neither well.

Migration reality

Anything holding regulated records leaves slowly. Approved promotional pieces, their reference sets, their approval signatures and their submission records have to remain retrievable, so plan to keep the incumbent readable rather than emptying it. For quality and regulatory content the same rules apply as any validated system: documents move with revision history and approvals, open workflows need a documented cutover position, and validation evidence follows the change.

If you are building a claims layer alongside the suite, the migration is different and much friendlier. You are not moving records, you are extracting knowledge: harvesting approved claims from historical pieces, attaching their references and having medical affairs confirm each one. That harvesting is the real work and it is done by people, not scripts. Budget a genuine number of medical and regulatory hours for it, and treat the resulting library as a governed asset with an owner and a review cycle.

Reviewer retraining is light if you keep the record in the suite and change only the assembly and triage layer, which is another argument for that shape of project.

Cost bands

Mid market life sciences suites are quoted per module and per user, generally below the market leader, with implementation and validation services on top. Specialist promotional review platforms price per user with volume tiers. Both are quoted rather than published, so build your comparison on three years of total cost including validation and internal staffing, not on the licence line.

On the custom side, based on what Digital Heroes typically delivers: a claims library and modular content assembly layer integrated with your existing review system, including reference linking and triage rules, runs roughly $60k to $150k over 10 to 18 weeks. A full custom review platform with parallel routing, annotation, channel specific workflows, digital asset handling, metrics and validation documentation runs roughly $200k to $400k as a one time build cost.

The honest recommendation

Stay if the suite is deployed, adopted and passing audits, because one validated platform across several disciplines is a real advantage that fragmented estates lose. Fix the process before you fix the tool, particularly in promotional review, where tiered review and fewer mandatory reviewers routinely cut cycle time more than any software change. Move to specialists only where one function is genuinely constrained by the shared model, and accept the integration cost that comes with it. Build the claims and assembly layer when digital volume has turned review into a bottleneck on commercial activity. That build does not replace your suite, it stops feeding it the same approved claim fifty times a quarter, and that is where the hours actually go.